An experimental treatment from Shionogi & Co Ltd has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday.
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.